GLP-1 Marketing Compliance: Claims a Supervised Weight Loss Clinic Can Back Up

GLP-1 marketing compliance comes down to four kinds of claims: what the drug is, what results patients get, what the program costs, and whose photos and reviews you show. Regulators have acted on all four in the last two years. A clinic that supervises patients in person can advertise its protocol, because a protocol is a fact you can document. This guide is part of the medical weight loss marketing series and shows how to turn supervision into marketing claims with a paper trail, and which claims to leave out.

It builds on the GLP-1 era differentiation playbook, which explains why supervision is the angle that holds up against telehealth. This article is about saying it in a way that survives an FDA letter, an FTC inquiry or a Meta review. I am not a lawyer and none of this is legal advice, so have a healthcare attorney in your state review your copy.

Key Takeaways

• The FDA says it does not review compounded drugs for safety, effectiveness or quality before they are marketed. It lists sameness claims about compounded drugs as a red flag.
• In February 2026 the FDA sent a warning letter citing website lines such as "the same active ingredient as FDA-approved medications."
• The FTC's NextMed order, approved December 3, 2025, requires competent and reliable evidence for claims about typical results, plus clear disclosure of refund and cancellation terms before payment.
• Meta requires weight loss and cosmetic ads to target people 18 or older and bars close-ups of pinching body fat and clickbait promises of outcomes within a set timeframe without qualifiers.
• Every claim on your site should map to a document in your clinic, such as a protocol, a lab policy or a visit schedule.
• Supervision claims hold up well because a protocol is a fact you can document.

What Regulators Have Targeted in GLP-1 Marketing

Enforcement so far has focused on sameness claims, unsupported results, hidden costs and fake proof. The table below summarizes the sources I opened for this guide.

State boards and attorneys general differ from state to state. Your attorney can tell you which of them watch your market.

GLP-1 Marketing Compliance Starts With Drug-Identity Claims

Describe the medication you actually prescribe, and do not compare a compounded product to an approved one. The FDA's GLP-1 page says the agency "does not review compounded drugs for safety, effectiveness or quality before they are marketed." The page showed content current as of October 1, 2026 when I read it. It also lists, as red flags for telehealth companies, claims that a compounded drug is the same as an FDA-approved drug.

A compounded drug is a medication a pharmacy mixes for an individual patient. The FDA does not review it for safety, effectiveness or quality before it is marketed.

The February 2026 warning letter to Lean Rx, doing business as SkinnyRx, shows what that means on a website. Among the lines the FDA cited was "Get access to the same active ingredient as name-brand GLP-1 medications." A second cited line said the product contains the same active ingredient as FDA-approved medications. The agency said the claims are false or misleading and that the products are misbranded under the Federal Food, Drug, and Cosmetic Act. It also objected to the seller's name on product labels, because that implied the seller compounds the drugs.

Three rules follow for your copy.

• If you prescribe an approved drug, name it accurately and describe your program around it.
• If you offer a compounded product, keep sameness language off your site and ads, and consider whether your attorney wants it described at all outside clinical conversation.
• Check every label and photo on your site for names or claims that imply approval or evaluation the product does not have.

The FDA page also reports adverse event data. It says the agency had received 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide as of May 31, 2026, and it says those counts are likely underreported. It describes dosing errors, including reports involving doses above the approved label or faster titration. That is a reason to describe your dosing as clinician-directed and individualized, which is also what a supervised program is.

Result Claims: Substantiate Before You Print a Number

Any average or typical result you publish needs evidence behind it. The FTC alleged that NextMed claimed members lose 53 pounds and 23% of their body weight on average without support. The final order requires "competent and reliable evidence to support claims about the average or typical results users will achieve."

For a clinic, three habits keep result copy safe.

1. Cite published trial results to their source. If you quote a clinical trial figure for the drug, link the trial and state the conditions, such as the dose and the duration. A trial figure describes the drug in a study population, so label it that way.
2. Publish your own outcomes only from tracked data. If you want to say what your patients achieve, you need a defined cohort, a start and end date, and the full denominator, including patients who left.
3. Skip the single standout case. The FTC's Health Products Compliance Guidance says attempts to disclaim dramatic results with statements like "Results not typical" do not fix a deceptive impression. It adds that dramatic testimonials should come with a clear disclosure of typical results.

If you cannot meet the second habit yet, describe your process instead of your outcomes. "Every patient gets a metabolic lab panel before the first dose and a monthly visit through titration" is a claim you can prove today.

Price and Program Claims

State what the advertised price includes and excludes. The FTC alleged that NextMed advertised monthly prices of typically $138 or $188 without adequately disclosing that the price excluded the GLP-1 drug, required lab work and a provider consultation. It also alleged that a 12-month commitment and early termination fee were not adequately disclosed.

A pricing page for a supervised program should answer these questions in plain language.

• What does the monthly fee cover: visits, labs, nutrition support, body composition scans?
• Is the medication included or billed separately, and at what price?
• Does an enrollment or assessment fee apply?
• Is there a commitment period, and what happens if the patient leaves early?
• How does a patient cancel, and how fast do you process it?

The order requires companies to get informed consent before billing and to provide a simple way to request cancellations. If your program bills automatically, the Restore Online Shoppers' Confidence Act also applies to online sign-ups. A published pricing page that states these terms is better for the patient and for AI search tools that quote your prices.

Photos, Testimonials and Reviews

Use only real patients, with consent, and avoid transformation pairs in ads. The FTC alleged that NextMed used deceptive before and after photos of people who were not its customers and published fake testimonials. It also alleged that the company offered gift cards to consumers who removed or changed negative reviews and conditioned refunds on review removal.

Meta's Health and Wellness policy requires weight loss ads to target people 18 or older. Its current list of things ads cannot do includes depicting a close-up of pinching body fat, claiming results from wearable products alone, and statements of inferiority about physical appearance. It also bars clickbait such as promising specific outcomes within a set timeframe without disclaimers or qualifiers. The July 2026 revision removed the earlier line barring side-by-side weight loss comparisons. Transformation pairs still carry FTC risk when the person is not a patient or the result is not typical, so treat each one as a claim you must substantiate. For weight loss products that require a prescription, the page points to Meta's drugs and pharmaceuticals policy and its geo-targeting and written permission requirements. Read the live wording before you build creative, since the page keeps a revision history.

On reviews, the FTC's consumer reviews rule bars offering incentives for reviews that express a particular sentiment. You can ask every patient for a review. My patient reviews guide covers a request process that stays on the right side of that line.

Build a Supervision Page You Can Document

Defensible GLP-1 marketing describes your protocol in specifics and keeps a document behind each statement. I call the working file a claims ledger. It has one row per claim on your site, with the proof next to it.

A claims ledger is a table that lists every factual claim on your site and ads, the document that backs it and the person who owns it.

Review the ledger every quarter. When the prescribing information, the FDA's guidance or your staffing changes, change the page the same week.

A supervision page built from the ledger can include the assessment steps, the monitoring schedule, who the clinician is and what happens when side effects or plateaus appear. It also states who the program is not a fit for, in plain language. That honesty is part of what makes it persuasive to a patient who is comparing you with a telehealth app. The weight loss SEO guide shows where that page sits in your site structure.

Platform Rules for GLP-1 Ads

Platform review is a second layer on top of law. Meta's page lists weight loss and cosmetic procedures together with an 18+ targeting requirement, and it routes prescription weight loss products through its drugs and pharmaceuticals policy, which adds geo-targeting and written permission requirements. Google has its own healthcare and medicines policy, so read the current version before you bid on drug terms. My Google Ads for doctors guide covers the account-level mechanics.

Two habits reduce friction. Build creative around the clinician, the visit and the program, which fits both platforms' rules. And keep your landing page claims identical to your ledger, so a reviewer who clicks through sees the same facts.

Pre-Launch Review Checklist

A platform I helped grow to $500M taught me to put the checklist before the launch date. Use the twelve checks below before any GLP-1 page or ad goes live.

1. The medication is named accurately, and no compounded product is described as the same as a brand-name drug.
2. No product label or photo implies approval or evaluation that does not exist.
3. Every result figure links to a trial or to your own tracked cohort with the full denominator.
4. No average or typical result appears without evidence behind it.
5. The price states what it includes and excludes, including medication, labs and visits.
6. Commitment length and cancellation steps appear where the patient pays.
7. Billing consent is captured as its own step.
8. Every photo and testimonial is from a real patient with written consent.
9. Every before and after image shows a consenting patient with a result you can show is typical, and no ad shows a close-up of pinching body fat.
10. Ads target people 18 and older, and copy does not state or imply inferiority about a person's appearance.
11. Reviews are requested from every patient, with no reward tied to sentiment.
12. A healthcare attorney in your state has reviewed the copy and the ledger.

When a Regulator or Platform Contacts You

Pause the claim, preserve the records and call your attorney before you reply. Take the page or ad down while you review it. Save the original copy, the dates it ran and the proof file behind it. Do not edit the old page in a way that hides what it said. A clean ledger makes this conversation shorter, because you can show what each claim rested on.

Questions practice owners ask

Can a clinic say its compounded semaglutide is the same as Ozempic or Wegovy?

The FDA lists claims that a compounded drug is the same as an FDA-approved drug as a red flag. Its February 2026 letter to an online seller of compounded GLP-1 products cited "same active ingredient" language. Describe your program and your clinical process instead, and ask your attorney how to describe any compounded option.

Can I advertise average weight loss results?

Only with evidence for the average. The FTC's NextMed order requires competent and reliable evidence for claims about average or typical results. Quoting a published trial with its conditions is different from implying your clinic gets the same outcome.

Are before and after photos allowed in GLP-1 ads?

Meta's current Health and Wellness text no longer lists side-by-side weight loss comparisons as prohibited, since its July 2026 revision, but it still bars close-ups of pinching body fat. The FTC has alleged deception where a company used photos of people who were not customers. Use real patients with consent and typical results, and have your attorney review any transformation creative before it runs.

What should a GLP-1 pricing page say?

It should state what the fee covers, whether medication is included, what labs and visits cost, any commitment period and how to cancel. The NextMed allegations centered on price exclusions and undisclosed commitment terms.

Does state law matter if I follow FDA and FTC rules?

Yes. Connecticut's Attorney General sent letters in May 2025 about advertising and prescribing compounded GLP-1 drugs, per a Foley & Lardner summary, and other states have their own rules. Your attorney can tell you how your state treats advertising by medical practices.

Can I market supervision as a differentiator?

Yes, provided each statement matches what your clinic does and you can document it. Keep a ledger of claims and proof, and update the page when the protocol changes.

Where to Start This Week

Pull every page and ad that mentions a GLP-1 drug and list each claim in a spreadsheet, one per row. For each row, write the proof document or delete the claim. Then send the list to your attorney. The weight loss clinic marketing guide covers the surrounding system.

This article describes regulator actions and platform policies as published and is not legal advice. Have a healthcare attorney review your advertising copy.